// App-Quantinova.ai

4508 : Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Researchers

Presenter

  • Darren R. Feldman

Principal Investigators

  • James Hu

  • Sandy Srinivas

  • Walter Michael Stadler

  • Brian Addis Costello

  • Leonard Joseph Appleman

  • Matthew I. Milowsky

  • Sujata Patil

  • Maria Bromberg

  • Patrick Nolan

  • Tanya B. Dorff

  • Victor E. Reuter

  • Hikmat Al-Ahmadie

  • Samuel Funt

  • Dean F. Bajorin

  • George J. Bosl

  • David I. Quinn

  • Robert J. Motzer

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • The University of Chicago Medical Center, Chicago, IL

  • Mayo Clinic, Rochester, MN

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • UNC Chapel Hill School of Medicine, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Progesterone receptor

  • Granulocyte colony-stimulating factor

  • Lactate dehydrogenase

Drug/Treatment

  • Levofloxacin

  • Ifosfamide

  • Paclitaxel

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

  • Bleomycin

  • Filgrastim

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • NCT01873326

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved